Ma Kewei, Li Enxi, Guo Ye, Wang Xingxing, Sun Hongwei, Shao Guoguang
Cancer Center, the First Hospital of Jilin University, Changchun 130021, China.
Email:
Zhonghua Zhong Liu Za Zhi. 2014 Jul;36(7):505-10.
The purpose of this study was to investigate the relationship between the expression of ribonucleotide reductase subunit M1 (RRM1) protein and the efficacy of gemcitabine/cisplatin (GP) adjuvant chemotherapy in postoperative non-small cell lung cancer (NSCLC) patients.
A total of 68 patients with NSCLC after radical surgery were included in this study. The expression of RRM1 protein in tumor specimens was assayed by streptavidin-peroxidase (SP) immunohistochemistry retrospectively. Correlation between the expression of RRM1 protein and the efficacy of GP chemotherapy was analyzed. Disease-free survival rate was taken as the main outcome measure.
Among the 68 patients, 31 cases had recurrence or metastasis. The expression rate of RRM1 was 54.4%. The 1-year and 3-year disease-free survival rates were 82.7% and 61.5% for patients with RRM1-negative expression, and 78.1% and 36.8% for patients with RRM1-posivive expression, respectively (P = 0.044). In the subgroup analysis of stage IB cases, the 1-year and 3-year disease-free survival rates were 100% and 82.3% for patients with RRM1-negative expression, and 84.5% and 24.6% for patients with RRM1-positive expression, respectively (P = 0.047). In the analysis of squamous cell carcinoma subgroup, the 1-year and 3-year disease-free survival rates were 92.3% and 83.7% for patients with RRM1-negative expression, and 83.1% and 43.9% for patients with RRM1-posivive expression, respectively (P = 0.005). Univariate analysis and multivariate analysis indicated that smoking history, pathological type, clinical stage and expression of RRM1 significantly influenced the therapeutic efficacy (P < 0.05).
RRM1 protein may be a valuable predictive factor for gemcitabine/cisplatin adjuvant chemotherapy in NSCLC patients.
本研究旨在探讨核糖核苷酸还原酶亚基M1（RRM1）蛋白表达与吉西他滨/顺铂（GP）辅助化疗对术后非小细胞肺癌（NSCLC）患者疗效之间的关系。
本研究共纳入68例接受根治性手术的NSCLC患者。采用链霉亲和素-过氧化物酶（SP）免疫组织化学方法回顾性检测肿瘤标本中RRM1蛋白的表达。分析RRM1蛋白表达与GP化疗疗效之间的相关性。以无病生存率作为主要观察指标。
68例患者中，31例出现复发或转移。RRM1的表达率为54.4%。RRM1阴性表达患者的1年和3年无病生存率分别为82.7%和61.5%，RRM1阳性表达患者分别为78.1%和36.8%（P = 0.044）。在IB期病例的亚组分析中，RRM1阴性表达患者的1年和3年无病生存率分别为百分之百和82.3%，RRM1阳性表达患者分别为84.5%和24.6%（P = 0.047）。在鳞状细胞癌亚组分析中，RRM1阴性表达患者的1年和3年无病生存率分别为92.3%和83.7%，RRM1阳性表达患者分别为83.1%和43.9%（P = 0.005）。单因素分析和多因素分析表明，吸烟史、病理类型、临床分期和RRM1表达对治疗疗效有显著影响（P < 0.05）。
RRM1蛋白可能是NSCLC患者吉西他滨/顺铂辅助化疗的一个有价值的预测因素。
